Clinical trials: Malignant Melanomas
Melanoma
Bevacizumab Combined With Carboplatin Plus Paclitaxel Chemotherapy to Treat Metastatic Mucosal Melanoma
Mucosal melanoma is rare and associated with extremely poor prognosis.No effective treatment for advanced mucosal melanoma patients.Investigators conducted a randomized phase II study in patients with previously untreated…
- Trial name
- NCT02023710
- Testing
- Paclitaxel, Carboplatin, Bevacizumab
- Where
- 3 sites in China
- Volunteers
- 182 people
- Sponsor
- Peking University Cancer Hospital & Institute
Melanoma (Skin Cancer)
A Comparative Usability Study of Two Total Body Skin Imaging Systems
This study aims to generate evidence on patient and dermatologist perspectives regarding two total body photography systems. Patient and clinician preferences represent key factors in healthcare decision-making.
- Trial name
- NCT07740642
- Testing
- Deviskan, Vectra WB360, Standard-of-care clinical examinations
- Where
- Switzerland
- Volunteers
- 60 people
- Sponsor
- University Hospital, Basel, Switzerland
Head and Neck Cancer Squamous Cell Carcinoma, Non-small Cell Lung Cancer
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
This study evaluates ADCT-301 in patients with Selected Advanced Solid Tumors. Patients will participate in a Treatment Period with 3-week cycles and a Follow-up Period every 12 weeks for up to 1 year after treatment…
- Conditions
- Head and Neck Cancer Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Gastric Cancer, Esophageal Cancer
- Trial name
- NCT03621982
- Testing
- ADCT-301, Pembrolizumab
- Where
- 9 sites in United States, Belgium and 1 more
- Volunteers
- 78 people
- Sponsor
- ADC Therapeutics S.A.
Malignant Melanoma
A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma
This is an open-label, multicenter, Phase Ib, dose-escalation and cohort-expansion study of atezolizumab (anti-programmed death-ligand 1 [PD-L1] antibody) in combination with vemurafenib or vemurafenib plus cobimetinib in…
- Trial name
- NCT01656642
- Testing
- Atezolizumab, Cobimetinib, Vemurafenib
- Where
- 8 sites in United States
- Volunteers
- 67 people
- Sponsor
- Genentech, Inc.
Malignant Melanoma, Squamous Cell Carcinoma of Skin
A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)
Primary Objective: -To determine the antitumor activity of SAR444245 in combination with cemiplimab. Secondary Objectives: To determine the recommended phase 2 dose and to assess the safety profile of SAR444245 when combined with…
- Trial name
- NCT04913220
- Testing
- THOR-707, Cemiplimab
- Where
- 24 sites in United States, Australia and 5 more
- Volunteers
- 46 people
- Sponsor
- Sanofi
Metastatic Malignant Neoplasm in the Liver, Metastatic Uveal Melanoma
Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma
This phase Ib trial studies the side effects and best dose of autologous CD8 positive (+) SLC45A2-specific T lymphocytes when given together with cyclophosphamide, aldesleukin, and ipilimumab, and to see how well they work in…
- Trial name
- NCT03068624
- Testing
- Aldesleukin, Autologous CD8+ SLC45A2-specific T Lymphocytes, Cyclophosphamide
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- M.D. Anderson Cancer Center
Melanoma, Non-small Cell Lung Cancer
A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors
The goal of this clinical research study is to learn how PLX3397 and pembrolizumab work together to affect cancer cells. PLX3397 is designed to target the receptor for CSF1 (CSF1R).
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Gastrointestinal Stromal Tumor (GIST)
- Trial name
- NCT02452424
- Testing
- PLX3397, Pembrolizumab
- Where
- 12 sites in United States
- Volunteers
- 78 people
- Sponsor
- Daiichi Sankyo
Precancerous Condition, Stage 0 Melanoma
Lovastatin in Treating Patients At High Risk of Melanoma
The use of lovastatin may slow disease progression in patients at high risk of melanoma. It is not yet known whether lovastatin is more effective than a placebo in treating patients at high risk of melanoma.
- Conditions
- Precancerous Condition, Stage 0 Melanoma, Stage I Melanoma, Stage II Melanoma
- Trial name
- NCT00462280
- Testing
- lovastatin, biopsy, laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- National Cancer Institute (NCI)
Anemia, Iron Deficiency, Melanoma
Intravenous Iron in Combination With Standard of Care Immunotherapy in Melanoma
Anemia is a common complication among cancer patients and is negatively associated with overall prognosis and therapeutic outcomes.
- Trial name
- NCT06508827
- Testing
- Iron dextran 1000 mg IV
- Sponsor
- Indiana University
Colorectal Cancer and Melanoma
Circulating Tumor Material in Colorectal Cancer and Melanoma
Observational study to allow the collection of blood and medical information to evaluate the role of circulating tumor material in patients with colorectal cancer and melanoma
- Trial name
- NCT02907086
- Testing
- blood collection
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Melanoma (Excluding Uveal Melanoma)
HS-IT101 Injection Versus Chemotherapy in the Treatment of Advanced Melanoma（FASTIL-Mela02）
This is a multicenter, randomized controlled, open-label Phase II clinical study designed to evaluate the efficacy and safety of HS-IT101 Injection versus the investigator's choice of chemotherapy in participants with advanced…
- Trial name
- NCT07406724
- Testing
- Tumor Tissue Sampling, Lymphodepletion Conditioning, Infusion of HS-IT101 Injection
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Hangzhou Huasai Biomedicine Co., Ltd.
Melanoma
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
This was a two-arm, double-blinded, randomized, Phase III study comparing dabrafenib and trametinib combination therapy to dabrafenib administered with a placebo (dabrafenib monotherapy).
- Trial name
- NCT01584648
- Testing
- Dabrafenib, Trametinib
- Where
- 121 sites in United States, Argentina and 12 more
- Volunteers
- 423 people
- Sponsor
- Novartis Pharmaceuticals
Hepatocellular Carcinoma (HCC), Metastatic Uveal Melanoma
A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors
This study is to evaluate the safety and tolerability to determine (i) the recommended Phase 2 dose (RP2D) of VMD-102 (Phase 1), and (ii) preliminary anti-tumor efficacy (Phase 2), in participants with advanced HCC, metastatic…
- Conditions
- Hepatocellular Carcinoma (HCC), Metastatic Uveal Melanoma, Renal Cell Carcinoma (RCC), Nonsmall Cell Lung Cancer
- Trial name
- SPKTAHC (NCT07636785)
- Testing
- VMD-102
- Where
- 2 sites in United States
- Volunteers
- 111 people
- Sponsor
- VM Discovery, Inc.
Metastatic Melanoma
RADVAX™: A STRATIFIED PHASE I/II DOSE ESCALATION TRIAL OF HYPOFRACTIONATED RADIOTHERAPY FOLLOWED BY IPILIMUMAB IN METASTATIC MELANOMA
The primary objective is to determine the maximum tolerated hypofractionated radiotherapy dose (MTD) to a solitary metastatic focus ('index lesion') when followed by ipilimumab, in metastatic melanoma patients without brain…
- Trial name
- NCT01497808
- Testing
- Ipilimumab, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma
Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer
This phase I trial studies the side effects and best dose of recombinant interleukin-15 in treating patients with melanoma, kidney cancer, non-small cell lung cancer, or head and neck cancer that has spread to other places in the…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Renal Cell Carcinoma
- Trial name
- NCT01727076
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Recombinant Human Interleukin-15
- Where
- 5 sites in United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma
Imatinib in Adult Patients With Metastatic Ocular Melanoma
The scope of the trial is to determinate the anti-tumoral activity of imatinib in metastatic ocular melanoma patients.
- Trial name
- O-Mel-Inib (NCT00421317)
- Testing
- Imatinib
- Where
- 12 sites in France
- Volunteers
- 13 people
- Sponsor
- Centre Oscar Lambret
Cutaneous Melanoma, Stage II, Malignant Cutaneous Melanoma
Evaluation of Oncoxin-Viusid® in Cutaneous Melanoma
Malignant melanoma, responsible for 75% of deaths from skin cancer. Current therapeutic options have poor response, many adverse events and high costs.
- Conditions
- Cutaneous Melanoma, Stage II, Malignant Cutaneous Melanoma, Cutaneous Melanoma, Stage III
- Trial name
- NCT03541148
- Testing
- Oncoxin-Viusid
- Where
- Cuba
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Catalysis SL
Advanced Cancers, Melanoma
Interstitial Fluid Pressure (IFP) Pilot Study in Melanoma Patients
The goal of this clinical research study is to learn about the side effects of measuring the tumor pressure in patients who have advanced melanoma and have not received chemotherapy.
- Trial name
- NCT01003626
- Testing
- Tumor Interstitial Fluid Pressure (IFP) assessments, Transducer-catheter SPC-320 + Amplifier
- Sponsor
- M.D. Anderson Cancer Center
Clinical Stage III Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary
A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma
This phase II trial studies the effect of pembrolizumab alone or in combination with CMP-001 in treating patients with melanoma that can be treated by surgery (operable).
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Recurrent Cutaneous Melanoma
- Trial name
- NCT04708418
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 187 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Melanoma
Response to Pembrolizumab in Metastatic Melanoma: Computed Tomography Texture Analysis as a Predictive Biomarker
Studies have shown that the study drug, pembrolizumab, works by helping the immune system. In this way, pembrolizumab may help to slow the growth of melanoma or may cause cancer cells to die.
- Trial name
- NCT02740920
- Testing
- Pembrolizumab, CT Scan
- Where
- 5 sites in Canada
- Volunteers
- 9 people
- Sponsor
- Canadian Cancer Trials Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.